Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QRFPR | Q96P65 | 3/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.56 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.54 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | NPY4R | P50391 | 1/20 | 0.53 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Laminin SCHEMBL29359946 | 0.92 | NTSR1 (0.56) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| Laminin SCHEMBL29354054 | 0.92 | NTSR1 (0.56) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29472195 | 0.90 | F2 (0.52) | NTSR1NTSR2OPRD1OPRK1 | |
| SCHEMBL29502186 | 0.88 | NPY4R (0.52) | QRFPRNPY1RNPY2RNPY4ROPRD1 | |
| SCHEMBL29671012 | 0.88 | NTSR1 (0.54) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL30405659 | 0.86 | NPY4R (0.53) | QRFPRNPY1RNPY2RNPY4ROPRD1 | |
| SCHEMBL31756855 | 0.85 | NTSR1 (0.66) | NTSR1NTSR2NPY1RNPY2RNPY4R | |
| SCHEMBL29374423 | 0.85 | QRFPR (0.63) | QRFPRNPY1RNPY2RNPY4ROPRK1 | |
| SCHEMBL29435086 | 0.84 | QRFPR (0.61) | QRFPRNPY1RNPY2RNPY4ROPRK1 | |
| SCHEMBL30211355 | 0.84 | NPY4R (0.52) | NPY1RNPY2RNPY4ROPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119604527-A | Anti-programmed death ligand 1 (PD-L1) antibodies | 安得泰医药有限公司 | 2025-03-11 | — | — | CN | claimed |
| EP-4486783-A2 | ANTI-PROGRAMMED DEATH-LIGAND 1 (PD-L1) ANTIBODIES | Adept Therapeutics Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| WO-2023164277-A2 | ANTI-PROGRAMMED DEATH-LIGAND 1 (PD-L1) ANTIBODIES | ADEPT THERAPEUTICS INC. (US) | 2023-08-31 | — | — | WO | claimed |
| US-20260108663-A1 | LOW PARTICULATE LUBRICIOUS COATING WITH VINYL PYRROLIDONE AND ACIDIC POLYMER-CONTAINING LAYERS | SURMODICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4633688-A1 | CELL-BINDING MOTIFS (CBMS) FUNCTIONALIZED POLYMERS | Universiteit Gent (BE) | 2025-10-22 | — | — | EP | disclosed |
| US-12409253-B2 | Low particulate lubricious coating with vinyl pyrrolidone and acidic polymer-containing layers | SURMODICS, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250171542-A1 | ANTI-PROGRAMMED DEATH-LIGAND 1 (PD-L1) ANTIBODIES | ADEPT BIOPHARMACEUTICAL AND TECHNOLOGY LTD. (CN) | 2025-05-29 | — | — | US | disclosed |
| EP-4486783-A2 | ANTI-PROGRAMMED DEATH-LIGAND 1 (PD-L1) ANTIBODIES | Adept Therapeutics Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-111050804-B | Non-covalently assembled biological matrix layers | 德诺沃迈瑞克斯有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024126517-A1 | CELL-BINDING MOTIFS (CBMs) FUNCTIONALIZED POLYMERS | UNIVERSITEIT GENT (BE) | 2024-06-20 | — | — | WO | disclosed |
| CN-110582567-B | Genetically modified trehalase-expressing yeasts and fermentation methods using such genetically modified yeasts | 嘉吉公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4276161-A2 | LOW PARTICULATE LUBRICIOUS COATING WITH VINYL PYRROLIDONE AND ACIDIC POLYMER-CONTAINING LAYERS | SurModics, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116829126-A | Hydrogel compositions and methods of use thereof | 小利兰·斯坦福大学托管委员会 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023164277-A2 | ANTI-PROGRAMMED DEATH-LIGAND 1 (PD-L1) ANTIBODIES | ADEPT THERAPEUTICS INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230167405-A1 | METHODS AND COMPOSITIONS OF PRO-ORGAN FORMATION ON PARTICLE SUBSTRATES AND USES THEREOF | HEROPHILUS, INC. | 2023-06-01 | — | — | US | disclosed |
| EP-2941279-B1 | LOW PARTICULATE LUBRICIOUS COATING WITH VINYL PYRROLIDONE AND ACIDIC POLYMER-CONTAINING LAYERS | SURMODICS INC (US) | 2023-05-17 | — | — | EP | disclosed |
| CN-109134603-B | 1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-formyl-GYIGSR, and synthesis, activity and application thereof | 首都医科大学 | 2022-04-22 | — | — | CN | disclosed |
| CN-109134603-B | 1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-formyl-GYIGSR, and synthesis, activity and application thereof | 首都医科大学 | 2022-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108663-A1 | LOW PARTICULATE LUBRICIOUS COATING WITH VINYL PYRROLIDONE AND ACIDIC POLYMER-CONTAINING LAYERS | VCL, RAD54L, SELP | QRFPR 1695/4885NTSR1 4667/4885NTSR2 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.